Histone Deacetylase Inhibitor Panobinostat Benefits the Therapeutic Efficacy of Oncolytic Herpes Simplex Virus Combined with PD-1/PD-L1 Blocking in Glioma and Squamous Cell Carcinoma Models

Background: Combination therapy has been widely explored for oncolytic virus (OV), as it can be met with tumor resistance. The HDAC inhibitor (HDACi) panobinostat is a potent pan-deacetylase inhibitor which blocks multiple cancer-related pathways and reverses epigenetic events in cancer progression....

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yinglin, Chen, Xiaoqing, Wang, Lei, Zhou, Xusha, Liu, Yonghong, Ji, Dongmei, Ren, Peigen, Zhou, Grace Guoying, Zhao, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781547/
https://www.ncbi.nlm.nih.gov/pubmed/36560800
http://dx.doi.org/10.3390/v14122796

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781547/
https://www.ncbi.nlm.nih.gov/pubmed/36560800
http://dx.doi.org/10.3390/v14122796

Ejemplares similares